Clinical trial
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients…
NCT00086775 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00086775 |
|---|---|
| Title | Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia |
| Official title | Phase II Trial Comparing Combination Treatment With Fludarabine and Alemtuzumab to Fludarabine and Rituximab in Patients With B-Cell Chronic Lymphocytic Leukemia Requiring Treatment After First Line Therapy |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | alemtuzumab, rituximab, fludarabine phosphate |
| Start date | Jul 1, 2003 |
| Primary completion | Jun 1, 2005 |
| Completion | Oct 1, 2009 |
| First posted | Jul 12, 2004 |
| Last update posted | Aug 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: